Gene Logic Announces Takeda Extension of BioExpress System Subscription
June 07 2005 - 7:00AM
Business Wire
Gene Logic Inc. (NASDAQ:GLGC) announced that Takeda Pharmaceutical
Company Limited has extended its subscription to Gene Logic's
BioExpress(R) System. The agreement with Takeda permits use of the
system as a primary tool for drug discovery and development. Takeda
extended their access to new BioExpress System data through 2006
and also obtained a perpetual license to the data existing as of
the commencement date of the latest agreement. Financial terms of
the agreement were not disclosed. The BioExpress System consists of
comprehensive genomic and clinical information derived from a broad
range of normal and diseased human tissues, treated and untreated
tissues from model animal systems and human and animal cell lines.
The BioExpress System and its related bioinformatics interface are
used by pharmaceutical companies for specific research and
development activities including data mining, analysis, indexing
and visualization. "Takeda is the largest pharmaceutical company in
Japan, and has been a very important client of ours for the past
three years," said Dennis Rossi, senior vice president and general
manager, genomics for Gene Logic. "We're pleased to continue
providing solutions to assist Takeda in their drug discovery and
development efforts. Japan is a significant market for our company
and a vital part of the global life sciences industry. We
established Gene Logic K.K., a wholly owned subsidiary in Tokyo
staffed with bilingual customer service and technical support
people, to better serve that market." Gene Logic Overview Gene
Logic aspires to be the most valued drug development solutions
provider for the pharmaceutical industry. Gene Logic applies its
broad and unique mix of technologies, talent and methodologies to
work on behalf of its partners to enable pharmaceutical and
biotechnology companies to make more informed, more reliable and
more predictive decisions at each point in the highly complex and
costly drug development process. For more information, visit
www.genelogic.com or call toll-free - 1/800/GENELOGIC.
Gene Logic Inc. (MM) (NASDAQ:GLGC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Gene Logic Inc. (MM) (NASDAQ:GLGC)
Historical Stock Chart
From Jul 2023 to Jul 2024